NPPA and depressive disorder: Their results suggests that plasma and CSF profiling of KP metabolites in depression can serve as proxy for accurate prognosis, evaluation of treatment options and highlights the potential utility of therapeutically targeting KP metabolism in depressive patients that are poor responders to existing pharmacotherapy [268].